Takeda Pharmaceutical Company Limited (TAK)
USD 13.11
(-1.87%)
USD 13.11
(-1.87%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | 900.32 Billion JPY | -22.15% |
| 2023 | 1156.46 Billion JPY | 14.91% |
| 2022 | 1183.21 Billion JPY | -10.4% |
| 2021 | 983.71 Billion JPY | 70.74% |
| 2020 | 880.32 Billion JPY | 82.77% |
| 2019 | 464.21 Billion JPY | -12.72% |
| 2018 | 359.95 Billion JPY | 10.75% |
| 2017 | 296.87 Billion JPY | 11.3% |
| 2016 | 349.85 Billion JPY | 135.76% |
| 2015 | 148.39 Billion JPY | -63.39% |
| 2014 | 368.18 Billion JPY | 15.42% |
| 2013 | 351.17 Billion JPY | -16.75% |
| 2012 | 421.81 Billion JPY | -12.91% |
| 2011 | 479.62 Billion JPY | -9.91% |
| 2010 | 537.63 Billion JPY | 21.43% |
| 2009 | 518.24 Billion JPY | -27.68% |
| 2008 | 608.86 Billion JPY | -2.33% |
| 2007 | 654.44 Billion JPY | 17.83% |
| 2006 | 547.05 Billion JPY | 10.82% |
| 2005 | 472.66 Billion JPY | -0.67% |
| 2004 | 474.58 Billion JPY | 9.99% |
| 2003 | 462.28 Billion JPY | 14.43% |
| 2002 | 402.61 Billion JPY | 32.13% |
| 2001 | 297.7 Billion JPY | 15.27% |
| 2000 | 237.32 Billion JPY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 366.1 Billion JPY | 105.34% |
| 2024 Q3 | 314.88 Billion JPY | 118.95% |
| 2024 FY | - JPY | 3.75% |
| 2024 Q4 | 374.02 Billion JPY | -70.51% |
| 2024 Q2 | 190.78 Billion JPY | -1.11% |
| 2023 Q1 | 369.22 Billion JPY | 204.4% |
| 2023 Q3 | 363.78 Billion JPY | 27.12% |
| 2023 FY | - JPY | 14.91% |
| 2023 Q4 | 252.25 Billion JPY | -30.66% |
| 2023 Q2 | 286.17 Billion JPY | -22.49% |
| 2022 FY | - JPY | -10.4% |
| 2022 Q3 | 236.98 Billion JPY | -1.98% |
| 2022 Q1 | 436.99 Billion JPY | 26.48% |
| 2022 Q4 | 121.29 Billion JPY | -48.82% |
| 2022 Q2 | 241.77 Billion JPY | -44.67% |
| 2021 Q2 | 198.08 Billion JPY | -37.85% |
| 2021 Q3 | 312.21 Billion JPY | 57.61% |
| 2021 Q4 | 345.51 Billion JPY | 10.66% |
| 2021 FY | - JPY | 70.74% |
| 2021 Q1 | 318.72 Billion JPY | 355.21% |
| 2020 Q1 | 197.21 Billion JPY | 300.04% |
| 2020 Q3 | 172.5 Billion JPY | -20.31% |
| 2020 Q4 | 70.01 Billion JPY | -59.41% |
| 2020 FY | - JPY | 82.77% |
| 2020 Q2 | 216.47 Billion JPY | 9.77% |
| 2019 Q3 | 108.2 Billion JPY | -6.27% |
| 2019 Q4 | 49.29 Billion JPY | -54.44% |
| 2019 FY | - JPY | -12.72% |
| 2019 Q2 | 115.44 Billion JPY | -21.59% |
| 2019 Q1 | 147.21 Billion JPY | 2158.43% |
| 2018 Q2 | 78.95 Billion JPY | -68.94% |
| 2018 FY | - JPY | 10.75% |
| 2018 Q4 | -7.15 Billion JPY | -106.8% |
| 2018 Q3 | 105.24 Billion JPY | 33.3% |
| 2018 Q1 | 254.2 Billion JPY | 1484.52% |
| 2017 Q1 | 198.85 Billion JPY | 931.02% |
| 2017 FY | - JPY | 11.3% |
| 2017 Q4 | 16.04 Billion JPY | -84.1% |
| 2017 Q3 | 100.9 Billion JPY | 37.11% |
| 2017 Q2 | 73.58 Billion JPY | -62.99% |
| 2016 Q1 | 103.47 Billion JPY | 141.84% |
| 2016 FY | - JPY | 135.76% |
| 2016 Q3 | 111.2 Billion JPY | -4.04% |
| 2016 Q2 | 115.88 Billion JPY | 11.99% |
| 2016 Q4 | 19.28 Billion JPY | -82.66% |
| 2015 Q3 | 170.13 Billion JPY | 55.73% |
| 2015 FY | - JPY | -63.39% |
| 2015 Q4 | -247.3 Billion JPY | -245.36% |
| 2015 Q2 | 109.25 Billion JPY | -6.06% |
| 2015 Q1 | 116.3 Billion JPY | 40.42% |
| 2014 Q2 | 133.63 Billion JPY | 34.88% |
| 2014 Q3 | 116.07 Billion JPY | -13.14% |
| 2014 Q4 | 82.82 Billion JPY | -28.64% |
| 2014 FY | - JPY | 15.42% |
| 2014 Q1 | 99.07 Billion JPY | 756.54% |
| 2013 Q4 | -15.09 Billion JPY | 94.09% |
| 2013 FY | - JPY | -16.75% |
| 2013 Q1 | 216.85 Billion JPY | 160.34% |
| 2013 Q2 | 203.75 Billion JPY | -6.04% |
| 2013 Q3 | -255.44 Billion JPY | -225.37% |
| 2012 Q1 | 221.1 Billion JPY | 187.98% |
| 2012 Q4 | -359.41 Billion JPY | -270.32% |
| 2012 Q3 | 211.01 Billion JPY | 6.08% |
| 2012 Q2 | 198.91 Billion JPY | -10.03% |
| 2012 FY | - JPY | -12.91% |
| 2011 Q4 | -251.31 Billion JPY | -203.62% |
| 2011 Q1 | 240.6 Billion JPY | 191.4% |
| 2011 Q2 | 252.53 Billion JPY | 4.96% |
| 2011 Q3 | 242.53 Billion JPY | -3.96% |
| 2011 FY | - JPY | -9.91% |
| 2010 FY | - JPY | 21.43% |
| 2010 Q3 | 252.32 Billion JPY | -5.55% |
| 2010 Q2 | 267.15 Billion JPY | -4.62% |
| 2010 Q4 | -263.23 Billion JPY | -204.32% |
| 2010 Q1 | 280.09 Billion JPY | 208.02% |
| 2009 Q4 | -259.3 Billion JPY | -186.93% |
| 2009 FY | - JPY | -27.68% |
| 2009 Q2 | 247.59 Billion JPY | 0.0% |
| 2009 Q3 | 298.29 Billion JPY | 20.48% |
| 2008 FY | - JPY | -2.33% |
| 2007 FY | - JPY | 17.83% |
| 2006 FY | - JPY | 10.82% |
| 2005 FY | - JPY | -0.67% |
| 2004 FY | - JPY | 9.99% |
| 2003 FY | - JPY | 14.43% |
| 2002 FY | - JPY | 32.13% |
| 2001 FY | - JPY | 15.27% |
| 2000 FY | - JPY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Amneal Pharmaceuticals, Inc. | 500.78 Million USD | -179684.417% |
| Bausch Health Companies Inc. | 2.88 Billion USD | -31107.21% |
| Catalent, Inc. | -284 Million USD | 317116.901% |
| Emergent BioSolutions Inc. | -505.29 Million USD | 178276.925% |
| Elanco Animal Health Incorporated | -224 Million USD | 402032.143% |
| Perrigo Company plc | 646.2 Million USD | -139226.524% |
| Teva Pharmaceutical Industries Limited | 4.33 Billion USD | -20678.398% |
| Zoetis Inc. | 3.68 Billion USD | -24332.239% |